Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ERS: Weekly Chemotherapy Schedule 'Slightly Superior' to Standard Regimen For Non-Small-Cell Lung Cancer By Crystal Phend GLASGOW, SCOTLAND -- September 15, 2004 -- A dose-adjusted weekly chemotherapy schedule using carboplatin and paclitaxel appears to be slightly more effective than the standard regime used for treatment of non-small-cell lung cancer (NSCLC). Combination therapy using two platinum agents is currently the standard of care for first-line treatment of NSCLC, said lead investigator Christian Schumann, MD, Department of Internal Medicine II, University of Ulm, Ulm, Germany. However, the preliminary results of a multicenter trial presented here September 6th at the European Respiratory Society 14th Annual Congress did not show clear superiority of one schedule over the other. The 867 chemo-naïve patients enrolled in the study had advanced NSCLC and were randomized either to a weekly schedule of carboplatin at an area-under-the-curve (AUC) of 2 and paclitaxel 100 mg/m2 or to a standard schedule of carboplatin at an AUC6 and paclitaxel 200 mg/m2 once every 3 weeks. Preliminary analysis of patients with sufficient follow-up to determine response to treatment included 767 participants, which was 97.6% of all patients. Of these, 223 had cancers in stage IIIb and 613 were in stage IV. The results were mixed. The weekly schedule had slightly better objective response rates, but survival and time to progression were somewhat better with the standard regimen. Complete response was achieved in 2.4% of patients on the weekly schedule and in 1.9% on the standard schedule. Partial response occurred in 33.9% of patients in the experimental arm and in 29.8% of the standard therapy arm. Median overall survival was 8.6 months for the weekly group and 9.3 months for the standard group. The time to progression was 6.7 months for the weekly schedule group and 7.7 months for the standard regime group. There were no significant differences in either hematologic or non-hematologic toxicities between the two dosing schedules. [Presentation title: "A Multicenter Randomized Phase III-Trial With Carboplatin (C) and Paclitaxel (P) in Advanced NSCLC: Preliminary Results of Dose Adjusted Weekly Schedule, Compared to Standard Regime (Q3W)." Abstract 1520] E-mail this page to a friend or colleague! To print, use this version